Amgen Cancer Treatment Candidate Had 'Adverse Events' in Almost Half of Patients

Shares of Amgen could face negative pressure Wednesday after the company released data from its phase 1 study on an investigational bispecific T cell engager molecules, updated with investigational AMG 420 results for the treatment of refractory multiple myeloma.